Asthma, Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the influencing factors during the COVID-19 epidemic.
Detailed description
During the COVID-19 epidemic, the medical treatment, disease status, and medication status of patients with chronic airway disease have not been studied. The purpose of this study is to investigate the management and healthcare utilization of patients with chronic airway disease and the relevant factors during the COVID-19 epidemic. Using cross-sectional research methods, telephone interviews and questionnaire surveys were used to investigate the management and healthcare utilization of patients with chronic airway disease （COPD and asthma）during the COVID-19 epidemic.
Interventions
OTHERNo intervention
No intervention
Sponsors
Peking University Third Hospital
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* COPD patients and asthma patients in the Chronic Airway Disease Database in Peking University Third Hospital.
Exclusion criteria
* Refusal to participate in this study; cognitive dysfunction.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Respiratory symptoms | through study completion, an average of 2 week. | COPD Assessment Test (CAT) |
| Frequency of exacerbation during the COVID-19 epidemic | through study completion, an average of 2 week. | Frequency of exacerbation during the COVID-19 epidemic |
Countries
China
Outcome results
None listed